DVA

AIEQ is accumulating DaVita, lifting its weight by 0.02pp to 0.31% on 2026-10-23, while QRFT holds only a token 0.04% position. This conflicts with the Fail verdict, since the framework objects to the leverage-inflated ROE and the lack of a clear margin of safety, though the small position sizes suggest the AIs are making a modest, valuation-driven bet rather than a high-conviction one.

• Circle of CompetenceDialysis is a steady, non-discretionary service with predictable patient volumes and recurring treatment revenue, so ten-year cash flows are reasonably modellable despite reimbursement exposure.
• Economic MoatDaVita holds a scale-driven advantage as one of two dominant US dialysis providers with dense clinic networks and nephrologist relationships, though heavy reliance on commercial-insurance mix and Medicare rates limits how unbreachable it is.
• ManagementManagement candour cannot be judged from the data given, though the company has historically bought back shares aggressively, which is a capital-allocation positive but is funded partly with debt.
• Financial HealthThe 181% ROE and 101x price-to-book come from a shrunken equity base after years of leveraged buybacks rather than from underlying earning power, and heavy debt plus thin net margins and capital-intensive clinics make the leverage a fragility that fails the manageable-debt test.
• Margin of SafetyA P/E of 14 and EV/EBITDA of 13.7 are reasonable but do not show a clear discount to a conservative intrinsic value given reimbursement risk and leverage, so a margin of safety is not evident.

DaVita is a predictable business with a real scale-based moat, so it clears the circle of competence and moat stages. Leverage-driven returns on equity and no obvious discount to intrinsic value cause it to fail on financial health and margin of safety, and management quality could not be fully verified from the data.

Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.